| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Net sales | ||||||
3,379 | 6,896 | 7,964 | 3,985 | - | - | - |
Cost of sales | ||||||
2,152 | 4,888 | 5,117 | 10,076 | - | - | - |
Net sales | ||||||
- | - | - | - | 8,950 | 3,398 | 1,565 |
Cost of sales | ||||||
- | - | - | - | 5,293 | 3,558 | 5,629 |
Gross profit | ||||||
1,227 | 2,008 | 2,847 | -6,091 | 3,657 | -160 | -4,064 |
Operating expenses: | ||||||
Research and development, net of grants | ||||||
13,143 | 10,005 | 7,893 | 5,347 | 3,036 | 5,041 | 3,249 |
Clinical and regulatory, net of grants | ||||||
3,354 | 4,600 | - | - | - | - | - |
Clinical and regulatory | ||||||
- | - | 3,062 | 2,703 | - | - | - |
Clinical and regulatory | ||||||
- | - | - | - | 3,510 | 2,622 | 3,215 |
Selling and marketing | ||||||
6,101 | 11,336 | 9,569 | 8,989 | 8,935 | 6,845 | 3,302 |
General and administrative | ||||||
9,226 | 10,692 | 10,932 | 10,080 | 8,223 | 6,565 | 4,168 |
Restructuring charges | ||||||
3,357 | 555 | - | - | - | - | - |
Total operating expenses | ||||||
35,181 | 37,188 | 31,456 | 27,119 | 23,704 | 21,073 | 13,934 |
Loss from operations | ||||||
-33,954 | -35,180 | -28,609 | -33,210 | -20,047 | -21,233 | -17,998 |
Interest income | ||||||
362 | 86 | 93 | 31 | 2 | 9 | 8 |
Other income, net | ||||||
- | - | - | - | 27 | 12 | 35 |
Interest expense on convertible promissory notes and loan payable | ||||||
- | - | - | - | - | 1,957 | 1,589 |
Amortization of discount on convertible promissory notes | ||||||
- | - | - | - | - | 5,077 | 3,425 |
Write-off of unamortized discount on conversion of convertible promissory notes | ||||||
- | - | - | - | - | 6,955 | 0 |
Net loss | ||||||
-33,592 | -35,094 | -28,516 | -33,179 | -20,018 | -35,201 | -22,969 |
Net loss per common share – basic and diluted | ||||||
-2.28 | -4.23 | -0.53 | -0.84 | -0.56 | -1.41 | -1.02 |
Weighted average shares outstanding – basic and diluted | ||||||
14,708 | 8,297 | 54,152 | 39,554 | 35,637 | 25 | 22 |